Complete chimerism following the use of anti-CD33 antibody in a child with relapsed acute lymphocytic leukemia (ALL) after allogeneic bone marrow transplantation (allo BMT)  by Odone-Filho, V. et al.
emphasize the importance of antigen-speciﬁc activation in the
selectivity of PDT for alloreactive T cells. Preservation of func-
tional T and B cells post-transplant should translate into protec-
tion against infectious agents and tumor cells.
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COMPLETE CHIMERISM FOLLOWING THE USE OF ANTI-CD33 ANTI-
BODY IN A CHILD WITH RELAPSED ACUTE LYMPHOCYTIC LEUKEMIA
(ALL) AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION (allo
BMT)
Odone-Filho, V.; Carvalho, A.; Ramos, R.R.; Conchon, M.; Cristofani,
L.M. Hospital Sirio Libanes, Sao Paulo, SP, Brazil.
The monoclonal anti-CD33 antibody (gemtuzumab ozogamicin:
GO) represents a therapeutic option for leukemic patients with
CD33-positive disease. Few reports relate its action in patients
with ALL who anomalously express CD33. We here report
GDRT, WM, diagnosed at the age of 4 years as having standard-
risk ALL, whose immunophenotypic expression included: CD34,
HLA-DR, TdT, CD19, CD79a, CD10 and also ectopic presence
of the myeloid antigens CD13 and CD33, treated as per the
Brazilian Cooperative Protocol-93, including: VCR, DEXA,
DAUNO, ASP and ARA-C as induction, high-dose MTX as in-
tensiﬁcation, maintenance with 6-MP, regular and high-dose
MTX and prophylactic intrathecal triple drugs (MADIT: MTX 
ARA-C  DEXA). Unsuccessful reinduction trials elicited by a
marrow recurrence after 12 months in remission were followed by
an allo-BMT, with active disease, the source of cells being the
cord-blood of his HLA-compatible sister. He did achieve a com-
plete engraftment, with normal XX marrow cells, which unfortu-
nately lasted less than 4 months. He was then referred with fully
active disease, over 60,000 blast cells/cu. mm., XX/XY chimera,
with the same initial immunophenotypic expression, hepatospleno-
megaly and adenomegaly, normal CSF and sepsis. Reinduction was
attempted with 8 cycles of VM-26 and ARA-C in 4 weeks followed
by TOPO and ETO, besides MADIT. Although there had been
disappearance of organomegaly and peripheral blast cells after the
3rd VM-26/ARA-C cycle, the marrow remained an M3 one even
13 days after TOPO/ETO exposure. Considering his anomalous
CD33 expression, GO, 3 mg/sq. m., 1-hour iv infusion was then
given. Marrow aplasia was veriﬁed after 7 days and an M1 marrow,
fully XX, was seen after 18 days. Maintenance plans included
monthly cycles of GO, as above, plus MADIT. Marrow sample
obtained at the 8th week after documented remission revealed
again blast cells, whose immunophenotypic expression continued
being the same, except for CD33 negativity. At the time of this
report the child continued being followed as outpatient, with
clearly progressive disease, however receiving only transfusional
support, with no additional therapeutic attempts. Interestingly, his
peripheral blood cells continued mostly being XX ones. GO was
capable of reproducing in a child with ALL and anomalous CD33
expression a complete chimera anteriorly obtained after an allo-
BMT. This might be an option for non-ablative procedures with
stem-cell reinfusion support.
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DEVELOPEMENT OF CHRONIC GVH IS THE STRONGEST PREDICTOR OF
SURVIVAL IN PATIENTS WITH POOR-RISK AML IN REMISSION AFTER
RELATED OR UNRELATED SCT
Fibich, C.1; Luiders, J.2; Douglas, S.2; Robert, T.A.2; Loree, L.2; Chris-
topher, B.2; Assan, C.2; James, R.A.2 1. Department of Hematology/
Oncology, Martin-Luther University, Halle/Saale, Germany; 2. Alberta
BMT Program, Calgary, AB, Canada.
High risk AML by clinical criteria, deﬁned as relapsed or refrac-
tory disease, primary induction-therapy failure, secondary AML or
advanced disease beyond 1st CR has a dismal outcome with all
current therapies. We analysed the inﬂuence of transplant-related
factors and GvHD on the outcome of adult pts with HR-AML who
underwent an allogeneic SCT in the Alberta Transplant Program.
Patients and methods: 105 adult pt median age 42, range 20 to 65y
were transplanted between 5/88 and 7/02. 71 pt received SCT
from related, 34 from matched unrelated donors. Indications for
allo-SCT were: 71 AML, 24 in 2nd CR, 18 refractory relapse, 15
primary induction failure and 14 untreated relapse. 34 pt had
secondary AML, either untreated (N26), refractory (N5) or
relapsed (N3). Conditioning-regimen used were: BuCy N43 (6
pt with ATG), CyTBI N17 (5 pt with ATG), FluBuATG N34,
VP16/TBI, N8, other N3. 62 pt received ATG (Sangstat,
Fresno, USA) and 31 pt TBI. Cytogenetic results were available for
23 adult pt at relapse or pre-BMT and for 25 pt at initial diagnosis.
Of these 3 were favorable (inv16, t8/21), 6 were normal karyotype,
and 8 other single translocations, and 29 were either complex
abnormal karyotype or high risk chromosomal aberrations (del 5q-,
del7). 3y OAS survival for all adult pt was 28% (95% CI: 20.03–
37.54%). No signiﬁcant differences in survival were found for
age-groups, cytogenetic risk-factors, MDS/AML vs AML, pres-
ence of aGvH I°. A trend for improved survival was found for pt
receiving TBI-containing regimen when compared to BuCY
(p0.064). The use of ATG in conditioning did not improve 100
d-OAS (no ATG 68.%, vs ATG 73%). Occurrence of cGvH
resulted in a highly signiﬁcant survival difference in favor of pts
with cGvH with a median survival of 760 vs 230 d (p0.002, HR
2.3) and a 3 y OAS of 47 vs 18% (p
0.01%). Chemotherapy-
intensity or donor-type did not signiﬁcantly inﬂuence outcome in
this poor-risk cohort. The only factor with highly signiﬁcant effect
on survival (p0.003) was the presence of chronic GvH suggesting
a graft vs leukemia effect requiring clinically evident GvH. The
beneﬁcial effect of ATG on early mortality that has been shown in
lower-risk pt-groups was not reproducible in this cohort possibly
due to the high early relapse rate (data not shown).
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ALLOGENEIC STEM CELL TRANSPLANTATION IN CHRONIC MYELOID
LEUKAEMIA: EXPERIENCE AT ARMED FORCES BONE MARROW TRANS-
PLANT CENTRE-PAKISTAN
Raza, S.; Hashmi, K.U.; Khattak, B.K.; Ahmed, P.; Hussain, I. Armed
Forces Bone Marrow Transplant Center, Rawalpindi, Punjab, Pakistan.
Objective: To evaluate the role and outcome of allogeneic stem
cell transplantation in chronic myeloid leukaemia in our popula-
tion. Methods: Cases suffering from chronic myeloid leukaemia
less than 50 years of age and having HLA matched sibling donor
received allogeneic stem cell transplantation. Conditioning was
done with busulphan 16 mg/kg plus cyclophosphamide 200 mg/kg
(Big Bu/Cy) or busulphan 16 mg/kg plus cyclophosphamide 120
mg/kg (Mini Bu/Cy), GVHD prophylaxis was given with Cyclo-
sporin (CSA) alone, or CSA plus Prednisolone with or without
short course of methotrexate. Patients received PBSC or bone
marrow alone or both. G-CSF was administered either on day 5
or 8 till ANC recovery. Engraftment was deﬁned as achievement
of neutrophil count of 0.5  109/l on 3 consecutive days. Pa-
tient’s engraftment and disease status were assessed at day 21, day
100 and thereafter every three months. Results: Since 5 April
2002 a total of 20 patients of chronic myeloid leukaemia underwent
allogeneic stem cell transplantation. Seventeen were male and 3
female. Median age of the patients was 29 years (range 7–50). 16
cases received PBSC, 1 bone marrow and 3 both. Mean mononu-
clear cell dose was 4.9  108/kg. Median time to neutrophil
recovery was 11.7 days (range 9–14). Neutropenic fever was seen in
80% cases, with mean duration of fever being 6.07 days. In ma-
jority no focus of infection was found. However cultures were
positive in 30% (n6) cases. Various isolates included gram-neg-
ative rods (n3); staphylococcus (n2) and fungi (n1) The com-
mon post engraftment infections were due to gram-negative rods,
tuberculosis, aspergillus, and herpes zoster. Other post-BMT com-
plications included acute GVHD 40%, chronic GVHD 15% and
hemorrhagic cystitis 15%. There were 4 (20%) deaths while in one
patient disease relapsed. Cause of death was septicaemia (n2),
DIC (n1) and disseminated aspergillosis (n1). The overall and
disease free survival (DFS) is 80% and 75% respectively. Mean
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